UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (date of earliest event reported): August 14, 2017

                               CEL-SCI CORPORATION
                          -----------------------------
             (Exact name of Registrant as specified in its charter)



          Colorado                        01-11889               84-0916344
 ---------------------------         ------------------      ----------------
(State or other jurisdiction        (Commission File No.)   (IRS Employer
of incorporation)                                            Identification No.)


                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
                     -------------------------------------
          (Address of principal executive offices, including Zip Code)


       Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
                     -------------------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

[ ] Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement  communications  pursuant to Rule 13e-14(c) under the
     Exchange Act (17 CFR 240.13e-4(c))



Item 8.01   Other Events

     On August 14, 2017 the Company  announced it has received a letter from the
U.S. Food and Drug  Administration  stating that the clinical hold that had been
imposed on the  Company's  Phase 3 cancer study with  Multikine has been removed
and that all  clinical  trial  activities  under this  Investigational  New Drug
application (IND) may resume.

     On August 14, 2017 the Company issued a press release, filed as Exhibit 99,
announcing the release of the clinical hold.


Item 9.01   Financial Statements and Exhibits

Exhibit       Description

99            Press Release dated August 14, 2017








                                       2


                                   SIGNATURES


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  August 14, 2017

                                     CEL-SCI CORPORATION


                                     By:  /s/ Patricia B. Prichep
                                       --------------------------------------
                                          Patricia B. Prichep
                                          Senior Vice President of Operations